Sustained drug release and improved product stability using non-covalent particle coating methods

• US 9,526,701 B2
• Filed: 12/20/2012
• Issued: 12/27/2016
• Est. Priority Date: 12/20/2011
• Status: Active Grant

• Current Assignee: Keith Latham
• Original Assignee: IPE, Inc.
• Inventors: Latham, Keith R.
• Primary Examiner(s): Skowronek, Karlheinz R
• Assistant Examiner(s): Fischer, Joseph
• Application Number:
  US13/721,733
• Publication Number:
  US 20130157992A1
• Time in Patent Office: 1,468 Days
• US Class Current: 1/1
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2063 Proteins, e.g. gelatin

Abstract

The present invention relates to improved methods of making compositions and compositions made by these methods having improved stability and/or extended release of an active agent or drug upon administration. These compositions may generally comprise an active agent or drug non-covalently immobilized or bound to an excipient substrate. The active agent or drug may include a wide variety of drugs. Binding of the active agent or drug to the substrate may be achieved by evaporating a solvent containing the active agent dissolved therein or by triggering co-precipitation by addition of a precipitating solvent. Additional steps of vacuum removal of surrounding atmosphere and replacement with inert gas may provide additional stability. Present methods and compositions also facilitate manufacturing of drug products and may make these processes safer in some cases. The present invention further provides improved methods of treatment or administration, which may take advantage of improvements with present compositions.

Claims

1. A method of stabilizing an active agent or drug comprising:

providing an active agent or drug hydrate having a bound water, wherein the active agent or drug degrades in the presence of water;

removing the bound water from the active agent or drug hydrate;

wherein removing the bound water from the active agent or drug hydrate further comprises;

dissolving the active agent or drug hydrate in a solvent, wherein the solvent consists of one or more independent solvents comprising 0.05% water by volume or less, wherein the solvent is capable of forming an azeotrope with a dissolved previously bound water of the active agent or drug hydrate;

wherein dissolving the active agent or drug hydrate in the solvent forms a solution comprising the dissolved active agent or drug and an azeotrope of the solvent and the dissolved previously bound water;

adding a substrate to the solution to form a suspension with the solution, wherein the substrate is a pharmaceutically suitable excipient; and

sequestering the dissolved previously bound water from the active agent or drug;

wherein sequestering the dissolved previously bound water further comprises depositing an anhydrous active agent or drug of the active agent or drug hydrate onto the substrate; and

evaporating the azeotrope until a substrate powder is formed, wherein at least one molecule of the anhydrous active agent or drug of the substrate powder is non-covalently bound to the substrate.

2. The method of claim 1, wherein evaporating the azeotrope further comprises placing the suspension under reduced pressure or vacuum, such that removal of respective partial pressures of the solvent and the evaporated dissolved bound water are reduced thereby causing evaporation of the respective solvent and the dissolved bound water from the suspension.

3. The method of claim 1, further comprising:

replacing the reduced pressure or vacuum with an inert gas.

4. The method of claim 3, further comprising:

vacuuming away the inert gas and replacing the vacuum with a second amount of inert gas.

5. The method of claim 1 wherein evaporating further comprises subjecting the suspension to an elevated temperature.

6. The method of claim 1, further comprising:

forming a final formulation, comprising the product of the method of claim 1, into one or more dosage forms;

placing the one or more dosage forms into a container; and

filling the container with an inert gas.

7. The method of claim 1, further comprising adding a capping agent to the solvent, wherein adding the capping agent is perfouned after sequestering and before evaporating, wherein the capping agent is selected from:

magnesium stearate, steric acid, stearyl fumarate, one or more peptides, or polyglutamic acid, and wherein the capping agent becomes non-covalently bound to the substrate.

8. The method of claim 1, wherein the solvent is tetrahydrofuran, ethanol, methyl ethyl ketone, ethyl acetate, or any combination thereof.

9. The method of claim 1, wherein the solvent is tetrahydrofuran.

10. The method of claim 1, wherein the solvent is ethanol.

11. The method of claim 1, wherein the active agent or drug is a thyroid hormone congener.

12. The method of claim 1, wherein the active agent or drug has high pharmacological activity when administered to an individual and therefore low mass load on the surface of the substrate when prepared for pharmaceutical use in individuals.

13. The method of claim 1, wherein the active agent or drug is selected from a hydrate of one or more of steroids, corticosteroids, cortisol, cortisone, corticosterone, hydrocortisone, prednisone, prednisolone, methylprednisolone, betamethasone, estrogen, peptide or non-steroidal hormones, insulin, thyroid hormones, thyroxine, triiodothyronine, catecholamines, catecholamine precursors, dopamine, L-DOPA, DOPA Cyclocarbonate, adrenergics, epinephrine, norepinephrine, amino acids, tyrosine, cysteine, serine, antibiotics, β

-lactam antibiotics, penicillins, cephalosporins, vitamins, vitamin A, vitamin E, narcotics, opioids, methadone, morphine, amphetamine, serotonergics, serotonin, chemotherapies, cytotoxic drugs, methotrexate, oxytocin, or heparin.

14. The method of claim 1, wherein the active agent or drug is one or more iodated L-thyronine congeners.

15. The method of claim 1, wherein the active agent or drug is one or more of a L-thyroxine, a L-thyronine, or a reverse T₃ (3,3′

,5′

-triiodo-L-thyronine).

16. The method of claim 1, wherein the active agent or drug is a levothyroxine.

17. The method of claim 1, wherein the substrate is cellulose, a cellulose derivative, controlled pore glass, a crystalline excipient, silica, silicate, activated carbon, or a polymer.

18. The method of claim 1, wherein the substrate is cellulose or a cellulose derivative.

19. The method of claim 3, wherein the inert gas is one or more of:

Nitrogen (N₂), Carbon Dioxide (CO₂), Argon (Ar), or Xenon (Xe).

20. The method of claim 1, wherein the amount of the active agent or drug by weight relative to the amount of the substrate by weight in the suspension is at a ratio from 1:

267 to 1;

2941.

21. The method of claim 1, wherein the amount of the active agent or drug by weight relative to the amount of the substrate by weight in the suspension is at a ratio of 1:

267.

22. The method of claim 1, wherein the amount of the active agent or drug by weight relative to the amount of the substrate by weight in the suspension is at a ratio of 1:

2941.

23. The method of claim 1, wherein simultaneously sequestering further comprises sequestering sodium away from the noncovalently bound active agent or drug.

24. The method of claim 1,

wherein the active agent or drug hydrate comprises a water of crystallization, and

wherein removing the previously bound water comprises removing the previously bound water of crystallization.

25. The method of claim 1, wherein the active agent or drug consists of a thyroid hormone congener,

wherein the substrate is cellulose or a cellulose derivative, and

wherein the solvent is tetrahydrofuran.

26. The method of claim 25, wherein the active agent or drug is a levothyroxine.

27. The method of claim 25, wherein the substrate of the substrate powder is anhydrous.

28. The method of claim 24, wherein removing the bound water further comprises removing all water of crystallization from the active agent or drug.

37. A sustained release composition comprising the substrate powder made by the method of claim 1.

38. The sustained release composition of claim 37, wherein the anhydrous active agent or drug is a thyroid hormone congener.

39. The sustained release composition of claim 38, wherein the thyroid hormone congener is Levothyroxine.

40. The sustained release composition of claim 38, wherein the thyroid hormone congener is Liothyronine.

41. The composition of claim 38, wherein the active agent or drug is one or more of a L-thyroxine, a L-thyronine, or a reverse T₃ (3,3′

,5′

-triiodo-L-thyronine).

29. A method of stabilizing a thyroid hormone congener comprising:

forming an azeotropic solution comprising dissolving a thyroid hormone congener hydrate in a solvent, wherein the azeotropic solution comprises the thyroid hormone congener dissolved in an azeotrope, the azeotrope comprising the solvent and a previously bound water from the thyroid hormone congener hydrate;

wherein the solvent comprises 0.05% water by volume or less before forming the azeotrope, and

forming an azeotropic suspension by adding a substrate to the azeotropic solution, wherein the substrate comprises a pharmaceutically suitable excipient; and

depositing an anhydrous thyroid hormone congener onto the substrate to form a substrate powder by evaporating the azeotrope from the azeotropic suspension until the substrate powder is formed,

wherein the substrate powder comprises at least one molecule of anhydrous thyroid hormone congener that was dehydrated from of the thyroid hormone congener hydrate during evaporating the azeotrope, and

wherein the anhydrous thyroid hormone congener is non-covalently bound to the substrate.

30. The method of claim 29,

wherein the thyroid hormone congener comprises levothyroxine, and

wherein the substrate comprises cellulose or a cellulose derivative.

31. The method of claim 30,

wherein the thyroid hormone congener hydrate is levothyroxine pentahydrate.

32. The method of claim 30, wherein the solvent comprises tetrahydrofuran.

33. The method of claim 29, wherein forming the azeotropic solution comprises dissolving a salt ion from the thyroid hormone congener hydrate in the azeotrope, the method further comprising:

sequestering the salt ion onto to the substrate during evaporating the azeotrope;

wherein the thyroid hormone congener consists of a levothyroxine salt,

wherein the substrate comprises cellulose or a cellulose derivative, and

wherein the substrate powder comprises the salt ion.

34. The method of claim 33, wherein the solvent consists of tetrahydrofuran and 0.05% water by volume or less before forming the azeotropic solution.

35. The method of claim 33,

wherein the salt ion consists of a sodium ion, and

wherein the thyroid hormone congener consists of a levothyroxine.

36. The method of claim 34, wherein the thyroid hormone congener hydrate consists of levothyroxine sodium pentahydrate.